But a recent survey of 100 urologists found that 57% "were unable to treat patients in the last 12 months due to a lack of ...

rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...

In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE ® BCG. The alternative BCG source ...

Supply shortages of TICE BCG in the U.S. have become a significant impediment to the treatment of bladder cancer patients. In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated ...

The SWOG 8795 study, with induction plus 1 year of maintenance therapy, demonstrated that 50 mg of TICE BCG improved RFS over MMC, but this was a low MMC dose of 20 mg in 20 mL. Notably ...

A bacteria-based immunotherapy product that has been used in the treatment of bladder cancer for the past 40 years is now in short supply, and it appears that the situation will continue for the ...

Merck said in an email that a "potential manufacturing issue" that arose in August 2014 has been addressed and that it has started to resupply Tice BCG. "In 2012, when Merck became the only ...

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

Merck, the sole supplier of a critical bladder cancer drug, is restricting shipments of the treatment as demand outpaces supply. In 2012, Merck became the only supplier of TICE BCG, a biologic ...

"Based on its common use, we estimate that more than 20 percent of the worldwide population is at risk to receive treatment with BCG Tice, a treatment that, based on our findings, is less ...